M. Ali

First name
Middle name
Last name
Ankarfeldt, M. Z., Thorsted, B. L., Groenwold, R. H., Adalsteinsson, E., Ali, M. S., & Klungel, O. H. (2017). Assessment of channeling bias among initiators of glucose-lowering drugs: A UK cohort study. Clin Epidemiol. http://doi.org/10.2147/clep.s124054
Khalid, S., Calderon-Larranaga, S., Hawley, S., Ali, M. S., Judge, A., Arden, N., et al. (2018). Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on "real-world" data: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database. Clin Epidemiol. http://doi.org/10.2147/clep.s164112
Robinson, D. E., Ali, M. S., Pallares, N., Tebe, C., Elhussein, L., Abrahamsen, B., et al. (2020). Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a bi-national cohort analysis. J Bone Miner Res. http://doi.org/10.1002/jbmr.4235
Alarkawi, D., Ali, M. S., Bliuc, D., Pallares, N., Tebe, C., Elhussein, L., et al. (2020). Oral bisphosphonate use and all-cause mortality in patients with moderate-severe (grade 3B-5D) chronic kidney disease: a population-based cohort study. J Bone Miner Res. http://doi.org/10.1002/jbmr.3961
Robinson, D. E., Ali, M. S., . Y. Strauss, V., Elhussein, L., Abrahamsen, B., Arden, N. K., et al. (2021). Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study. Health Technol Assess. http://doi.org/10.3310/hta25170